Kiora Pharmaceuticals, Inc.
KPRXHealthcare|Biotechnology|US
$1.44
-0.06 (-4.00%)
DCF Value
$2.55
Tangible Book / Share
$2.39
Cash / Share
$2.73
Analyst Consensus
Buy3 analysts
Strong Buy
0
Buy
3
Hold
0
Sell
0
Strong Sell
0
Rating Trend
Dec 25
1 buy · 0 hold · 0 sell
Jan 26
1 buy · 0 hold · 0 sell
Feb 26
1 buy · 0 hold · 0 sell
Mar 26
1 buy · 0 hold · 0 sell
Apr 26
1 buy · 0 hold · 0 sell
May 26
1 buy · 0 hold · 0 sell
Jun 26
1 buy · 0 hold · 0 sell
Jul 26
1 buy · 0 hold · 0 sell
Aug 26
1 buy · 0 hold · 0 sell
Sep 26
1 buy · 0 hold · 0 sell
Oct 26
1 buy · 0 hold · 0 sell
Nov 26
1 buy · 0 hold · 0 sell
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 2, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 28, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 12, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 22, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 23, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 20, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 27, 2024 |
| HC Wainwright & Co. | maintain | Buy | Feb 9, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 13, 2023 |
| HC Wainwright & Co. | maintain | Buy | Nov 6, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 24, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 14, 2023 |
| Maxim Group | maintain | Buy | Aug 9, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 12, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 24, 2023 |
| Maxim Group | upgrade | Hold →Buy | Feb 9, 2023 |
| HC Wainwright & Co. | maintain | Buy | Feb 8, 2023 |
| Ladenburg Thalmann | maintain | Buy | Feb 8, 2023 |
| Ladenburg Thalmann | maintain | Buy | Aug 25, 2022 |
| Maxim Group | downgrade | Buy →Hold | Aug 15, 2022 |
| HC Wainwright & Co. | maintain | Buy | Jul 11, 2022 |
| HC Wainwright & Co. | maintain | Buy | Apr 19, 2022 |
| Maxim Group | maintain | Buy | Jan 19, 2022 |
Earnings History
Next report: Mar 30, 2027 · EPS est. $-0.13| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 7, 2026 | $-0.34 | $-0.47 | — | — |
| May 8, 2026 | $-0.58 | $-0.71 | — | $1.5M |
| Mar 25, 2026 | $-1.60 | $-0.67 | — | $1.5M |
| Nov 7, 2025 | $0.01 | $-0.72 | — | $750.0K |
| Aug 8, 2025 | $-0.54 | $-0.58 | — | $750.0K |
| May 9, 2025 | $-0.52 | $-0.77 | — | $750.0K |
| Mar 25, 2025 | $-1.04 | $-0.64 | — | $750.0K |
| Nov 8, 2024 | $-0.81 | $-0.90 | — | $750.0K |
News
Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
Encinitas, California--(Newsfile Corp. - August 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora") today announced that it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation (CKD). CKD, based in Seoul, is one of South Korea's leading pharmaceutical companies.
Aug 19, 2026newsfilecorp.com